secwatch.observer — SEC 8-K summary
======================================

Issuer:     CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL)
CIK:        0001100682
Form:       8-K
Filed at:   2022-11-02T23:59:59+00:00
Accession:  0001157523-22-001470
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Charles River Q3 revenue $989.2M (+10.4% YoY); raises guidance, plans Avian Vaccine sale for ~$170M
--------------------------------------------------------------------------------

- Q3 revenue $989.2M (+10.4% YoY, organic +15.3%); GAAP EPS $1.88 (-6.5%), non-GAAP EPS $2.63 (-2.6%).
- DSA segment revenue $619.5M (+16.5%) drove results; Manufacturing declined -1.7% to $189.6M.
- Narrows 2022 guidance: reported revenue growth 10-11%, non-GAAP EPS $10.80-10.95 (prior $10.70-10.95).
- Announced divestiture of Avian Vaccine business for ~$170M cash plus up to $30M contingent; close expected by year-end.
- Divestiture to reduce 2023 revenue by ~$80M and non-GAAP EPS by ~$0.35 before redeployment of proceeds.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1100682/000115752322001470/0001157523-22-001470-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1100682/000115752322001470/a52958171.htm
  HTML page:      https://secwatch.observer/filing/0001157523-22-001470

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer